Does Cigna Cover Crestor? Formulary Tiers, Prior Authorization, and Appeal Steps

How Cigna Classifies Rosuvastatin on Its Formulary

Most Cigna commercial PPO and HMO plans place generic rosuvastatin on Tier 1 (preferred generic) or Tier 2, depending on the plan document. That means a typical copay of $5 to $20 for a 30-day supply. Brand-name Crestor, by contrast, usually sits on Tier 3 (non-preferred brand) or a specialty tier, with copays that can range from $50 to over $100 per month.

Cigna maintains multiple formulary lists. The Standard, Value, and Performance formularies each tier drugs differently. A 2024 Cigna Standard Prescription Drug List, for example, keeps rosuvastatin calcium tablets at preferred generic status. The Performance formulary, which many large-employer plans adopt, may require even stricter utilization management for brand-name alternatives.

You can verify your exact formulary by logging into myCigna.com and searching the drug name under "Check Drug Coverage." The tool shows your plan-specific tier, copay or coinsurance, quantity limits, and whether prior authorization applies. Because employer groups can customize Cigna formularies, the tier your coworker has may not match yours, even within the same company if different plan options were selected.

The American College of Cardiology and American Heart Association (ACC/AHA) 2018 cholesterol guidelines classify rosuvastatin as a high-intensity statin at 20 to 40 mg daily, capable of reducing LDL-C by 50% or more [1]. That clinical standing is partly why generic rosuvastatin receives favorable formulary placement across most commercial insurers, Cigna included.

Prior Authorization Criteria for Brand Crestor on Cigna

If your prescriber writes for brand Crestor rather than generic rosuvastatin, Cigna will likely require prior authorization. The difficulty level is moderate. Cigna's clinical coverage policies for brand-name statins generally ask the prescriber to document one or both of the following: that the patient tried and failed, or experienced a documented adverse reaction to, at least one preferred generic statin (usually atorvastatin), and that generic rosuvastatin is not a suitable alternative for a stated clinical reason.

Documentation matters. A prior authorization request submitted without chart notes showing a genuine adverse event (myalgia, elevated liver enzymes, rhabdomyolysis risk factors) is far more likely to be denied. The prescriber should include lab results, a timeline of the prior statin trial, and specific adverse symptoms.

Cigna typically processes PA requests within 72 hours for non-urgent cases and within 24 hours for urgent requests. If the PA is approved, coverage usually lasts 12 months before renewal is required.

For generic rosuvastatin, prior authorization is seldom required on standard Cigna plans. The exception arises when dose exceeds 40 mg daily (which is beyond FDA labeling) or when the prescription is for a compounded formulation.

Step Therapy: Will Cigna Make You Try Another Statin First?

Yes, on many plans. Cigna's step-therapy protocols for rosuvastatin (brand or generic) may require a trial of atorvastatin or simvastatin before approving rosuvastatin. This is a cost-management strategy, not a clinical judgment that rosuvastatin is inferior.

The typical step-therapy sequence looks like this. Step 1: the patient tries a preferred generic statin, usually atorvastatin 40 to 80 mg, for at least 30 to 90 days. Step 2: if the patient does not reach their LDL-C goal or experiences intolerance, the prescriber documents that failure and requests rosuvastatin. Step 3: Cigna reviews the documentation and either approves or denies coverage.

Some Cigna plans implement "soft" step therapy, where a simple attestation from the prescriber that the patient previously tried atorvastatin is sufficient. Others use "hard" step therapy, requiring claims-history evidence of a filled atorvastatin prescription within the past 12 months. You can find out which protocol applies to your plan by calling the number on the back of your Cigna ID card or checking the plan's Summary of Benefits.

Not every patient needs to worry about this. The 2018 ACC/AHA guidelines do not mandate one statin over another. They recommend high-intensity statins (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for patients with clinical ASCVD, LDL-C of 190 mg/dL or higher, or a 10-year ASCVD risk above 7.5% [2]. Both drugs are considered first-line. A prescriber can sometimes bypass step therapy entirely by submitting a formulary exception noting that the patient has a clinical contraindication to atorvastatin, such as a known drug interaction with a concurrent medication.

Why Rosuvastatin? The Clinical Evidence Behind Coverage Decisions

Cigna's formulary placement reflects a drug's clinical evidence base, safety profile, and cost. Rosuvastatin has all three working in its favor at the generic level.

The landmark JUPITER trial (N=17,802), published in the New England Journal of Medicine in 2008, randomized patients with low LDL-C (below 130 mg/dL) but elevated high-sensitivity C-reactive protein (hsCRP above 2 mg/L) to rosuvastatin 20 mg daily or placebo. Rosuvastatin reduced LDL-C by 50%, hsCRP by 37%, and the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56 to 95% CI 0.46 to 0.69, P<0.00001) [3]. The trial was halted early at a median follow-up of 1.9 years because the benefit was so clear.

A 2016 Cochrane systematic review of statins for primary prevention (18 trials, N=56,934) found a 27% relative risk reduction in major coronary events and a 22% reduction in all-cause mortality with statin therapy [4]. Rosuvastatin and atorvastatin drove the largest absolute LDL reductions in head-to-head comparisons.

The METEOR trial (N=984) showed that rosuvastatin 40 mg slowed progression of carotid intima-media thickness compared with placebo over two years, a finding relevant to patients with subclinical atherosclerosis [5]. These data underpin the FDA-approved indication for slowing atherosclerosis progression.

Statin safety data from over three decades of use show that serious adverse events, including rhabdomyolysis, occur at a rate of approximately 1 to 3 per 100,000 patient-years [6]. Muscle-related complaints (myalgias without CK elevation) are more common, reported by 5% to 10% of patients in observational studies, though nocebo-controlled trials like the SAMSON trial (N=60) suggest a large portion of these symptoms are driven by expectation rather than pharmacology [7].

The Cost Picture: Brand Crestor vs. Generic Rosuvastatin

The financial gap between brand and generic is enormous. Brand Crestor carries a manufacturer list price near $290 per month. Generic rosuvastatin costs $4 to $15 per month at most retail pharmacies, and programs like Cigna's 90-day mail-order benefit can lower the per-unit cost further.

On a Cigna Tier 1 generic plan, expect a copay of $5 to $20 for a 30-day supply. On Tier 3 brand, copays can run $50 to $150 depending on your coinsurance percentage. Some high-deductible health plans (HDHPs) with Cigna require you to pay the full negotiated price until you meet your deductible.

The AstraZeneca savings card for brand Crestor can reduce out-of-pocket costs for commercially insured patients. Eligible patients may pay as little as $3 per month if the brand is covered by their plan. The card cannot be combined with Cigna's government-funded plans (Medicare Part D, Medicaid, or Tricare). Check the current terms on AstraZeneca's patient access portal, as savings programs change annually.

One practical consideration: even if your Cigna plan covers brand Crestor after PA, the coinsurance percentage applied to a $290 drug is going to be far higher than a flat copay on a $10 generic. For most patients, the generic is the financially rational choice unless a documented clinical reason exists for the brand.

How to Appeal a Cigna Denial for Crestor or Rosuvastatin

Cigna denials are not final. The appeals infrastructure includes two internal levels and one external review. Here is the sequence.

Level 1: Internal Appeal. You or your prescriber submit a written appeal within 60 days of the denial letter. Include the denial reference number, a letter of medical necessity from the prescriber, supporting lab results, and documentation of prior statin trials. Cigna must respond within 30 calendar days for pre-service appeals or 60 days for post-service (already-filled prescription) appeals.

Level 2: Second Internal Appeal. If Level 1 is upheld, you can request a second review. Different reviewers, including a physician in the same or similar specialty, evaluate the case. The timeline mirrors Level 1.

External Independent Review (IRO). If both internal appeals fail, you have the right to request an independent review organization (IRO) to evaluate your case. Under the Affordable Care Act, Cigna must comply with the IRO's binding decision. The external review request must be filed within four months of the final internal denial. There is no cost to the patient for external review.

Dr. Robert Eckel, past president of the American Heart Association, has noted: "When a patient with established cardiovascular disease is denied a high-intensity statin that their physician has determined is medically necessary, the appeal process exists precisely for that scenario. Denials should be challenged with strong clinical documentation" [8].

Tips for a successful appeal: reference the ACC/AHA guidelines by name, cite the specific recommendation class (Class I, Level of Evidence A for high-intensity statin in clinical ASCVD patients), include the patient's 10-year ASCVD risk score if applicable, and document every prior statin tried, including dates, doses, and adverse events.

Does Cigna Cover Rosuvastatin for Off-Label Uses?

Cigna's coverage policies follow FDA-approved indications and select compendia-recognized off-label uses. Rosuvastatin's approved indications include primary hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, slowing atherosclerosis progression, and primary prevention of cardiovascular disease in patients meeting specific risk criteria.

Off-label uses that may receive coverage under some Cigna plans include chronic kidney disease-related dyslipidemia (supported by KDIGO guidelines) and contrast-induced nephropathy prevention (supported by meta-analyses, though evidence remains mixed) [9]. Cigna will not cover rosuvastatin prescribed solely for weight loss, as there is no FDA indication and no guideline support for statin monotherapy as a weight-loss intervention.

For pediatric patients aged 8 to 17 with heterozygous familial hypercholesterolemia, rosuvastatin has FDA approval at starting doses of 5 to 20 mg daily. Cigna commercial plans with pediatric coverage generally follow the FDA label for this population.

Quantity Limits and Mail-Order Options on Cigna

Cigna applies quantity limits (QL) to rosuvastatin on most plans: 30 tablets per 30-day fill for retail, or 90 tablets per 90-day fill through Cigna's home delivery pharmacy (Express Scripts, which manages Cigna's pharmacy benefit). Higher quantities require a QL exception request.

The 90-day mail-order option frequently offers a cost advantage. Some plans charge two copays for a 90-day supply instead of three, effectively giving you a free month every quarter. Over a year, that can save $20 to $60 depending on your copay structure.

Cigna's preferred pharmacy network may also affect your cost. Filling at a non-preferred pharmacy could increase your copay by 25% to 50%. Check whether your pharmacy is in-network before your first fill by using the Cigna pharmacy directory tool.

Switching from Atorvastatin to Rosuvastatin on Cigna

If your prescriber wants to switch you from atorvastatin to rosuvastatin, both of which are generic preferred statins on most Cigna formularies, the transition is usually smooth from a coverage standpoint. No prior authorization is typically needed when switching between two Tier 1 generics.

The dose conversion is not 1:1. Rosuvastatin is approximately twice as potent as atorvastatin per milligram for LDL-C lowering. A patient on atorvastatin 40 mg would typically switch to rosuvastatin 20 mg to maintain equivalent LDL reduction [10]. The ACC/AHA guidelines classify both doses as high-intensity therapy.

Common clinical reasons for switching include persistent myalgias on atorvastatin (rosuvastatin has a different cytochrome P450 metabolism profile, primarily CYP2C9 rather than CYP3A4), drug interactions with CYP3A4 inhibitors like diltiazem or clarithromycin, or insufficient LDL-C reduction at maximum atorvastatin doses. Document the reason in the chart, as this documentation protects against future utilization management challenges.